The use of FISH, which has also been validated on TMAs [26], to clarify the HER2 status of both the primary and recurrent disease by an accredited cytogenetics service should give confidence that the progression to HER2 amplification demonstrated here in 2.2% of cancers accurately reflects cytogenetic gain in the relapsed disease compared with the primary cancer. Here, ERBB2 is linked to cancer.